Defining neuroblastoma: From origin to precision medicine
Lourdes Sainero‐Alcolado, Tomas Sjöberg Bexelius, Giuseppe Santopolo, Ye Yuan, Judit Liaño-Pons, Marie Arsenian‐Henriksson
Abstract
Neuroblastoma (NB), a heterogenous pediatric tumor of the sympathetic nervous system, is the most common and deadly extracranial solid malignancy diagnosed in infants. Numerous efforts have been invested in understanding its origin and in development of novel curative targeted therapies. Here, we summarize the recent advances in the identification of the cell of origin and the genetic alterations occurring during development that contribute to NB. We discuss current treatment regimens, present and future directions for the identification of novel therapeutic metabolic targets, differentiation agents, as well as personalized combinatory therapies as potential approaches for improving the survival and quality of life of children with NB.